579 related articles for article (PubMed ID: 23964122)
1. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
2. Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis.
Qin L; Thompson LF; Kuzel TM; Zhang B
Immunotherapy; 2014; 6(1):19-21. PubMed ID: 24341879
[TBL] [Abstract][Full Text] [Related]
3. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
4. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
5. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
6. CD73 on cancer-associated fibroblasts enhanced by the A
Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
[TBL] [Abstract][Full Text] [Related]
7. Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Carmo M; Gonçalves FQ; Canas PM; Oses JP; Fernandes FD; Duarte FV; Palmeira CM; Tomé AR; Agostinho P; Andrade GM; Cunha RA
Br J Pharmacol; 2019 Sep; 176(18):3666-3680. PubMed ID: 31220343
[TBL] [Abstract][Full Text] [Related]
8. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
Stagg J; Divisekera U; McLaughlin N; Sharkey J; Pommey S; Denoyer D; Dwyer KM; Smyth MJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1547-52. PubMed ID: 20080644
[TBL] [Abstract][Full Text] [Related]
10. CD73-generated adenosine promotes osteoblast differentiation.
Takedachi M; Oohara H; Smith BJ; Iyama M; Kobashi M; Maeda K; Long CL; Humphrey MB; Stoecker BJ; Toyosawa S; Thompson LF; Murakami S
J Cell Physiol; 2012 Jun; 227(6):2622-31. PubMed ID: 21882189
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.
Wang L; Fan J; Chen S; Zhang Y; Curiel TJ; Zhang B
PLoS One; 2013; 8(3):e58397. PubMed ID: 23520507
[TBL] [Abstract][Full Text] [Related]
12. Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation.
Ohtsuka T; Changelian PS; Bouïs D; Noon K; Harada H; Lama VN; Pinsky DJ
J Immunol; 2010 Jul; 185(2):1321-9. PubMed ID: 20548026
[TBL] [Abstract][Full Text] [Related]
13. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
15. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A
Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS
J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752
[TBL] [Abstract][Full Text] [Related]
16. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
17. Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts.
Methner C; Schmidt K; Cohen MV; Downey JM; Krieg T
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1262-4. PubMed ID: 20709859
[TBL] [Abstract][Full Text] [Related]
18. CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages.
Murphy PS; Wang J; Bhagwat SP; Munger JC; Janssen WJ; Wright TW; Elliott MR
Cell Death Differ; 2017 Mar; 24(3):559-570. PubMed ID: 28060378
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1.
García-Rocha R; Monroy-García A; Hernández-Montes J; Weiss-Steider B; Gutiérrez-Serrano V; Del Carmen Fuentes-Castañeda M; Ávila-Ibarra LR; Don-López CA; Torres-Pineda DB; de Lourdes Mora-García M
Cytokine; 2019 Jun; 118():71-79. PubMed ID: 30301599
[TBL] [Abstract][Full Text] [Related]
20. Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A
Dziedzic K; Węgrzyn P; Gałęzowski M; Bońkowska M; Grycuk K; Satała G; Wiatrowska K; Wiklik K; Brzózka K; Nowak M
Int Immunopharmacol; 2021 Jul; 96():107645. PubMed ID: 33894488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
